BRTX vs REGN · rev $401.0K vs P/E 14, rev $14.34B
BioRestorative Therapies Inc (BRTX) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
BioRestorative Therapies Inc (BRTX) is a biotechnology company listed on NASDAQ.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported BRTX revenue for 2024-12-31 was $401.0K. Net income was -$9.0M. Revenue was up 175.0% from 2023-12-31 to 2024-12-31. BRTX currently screens at market cap $10.2M.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
BRTX currently screens at market cap $10.2M. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the BRTX and REGN stock pages for the full models.
Not investment advice.